Finding Emotional Honesty in the Complicated Extremes of Cancer
Living with metastatic breast cancer isn’t easy. For me, one of the struggles has been with the uncertainty of this disease, which... Read More
Dramatic Advances in HER2+ Breast Cancer over the Past 10 Years
In an interview with OncLive, Dr. Sara Hurvitz, from UCLA, discusses ongoing advances that continue to revolutionize the treatment of patients with HER2+... Read More
Phase III Breast Cancer Drug Abemaciclib Improves PFS
This CDK inhibitor will ultimately join palbociclib and ribociclib as an option for heavily pretreated MBC ER/PR+ patients who would take... Read More
FDA Approves Kisqali for Breast Cancer
Kisqali (ribociclib), a CDK 4/6 inhibitor, gained approval from the Food and Drug Administration (FDA) for the frontline treatment of postmenopausal women... Read More
The U.S. Food and Drug Administration has approved Ibrance (palbociclib)
The approval is based on findings from the phase 3 PALOMA-3 trial, in which adding Ibrance to standard Faslodex more than... Read More
Advocacy Group Helps Patients Cope
For two years after Shirley Mertz was diagnosed with metastatic breast cancer, she didn’t meet a single other person with the disease.... Read More